Advertisement

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x100px
Organisation › Details

Owkin (Group)

Owkin is the first end-to-end TechBio company on a mission to understand complex biology and derive new multimodal biomarkers through AI. We identify precision therapeutics, de-risk and accelerate clinical trials and develop diagnostics using AI trained on world-class patient data through privacy-enhancing federated technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular, immunity and inflammation. Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research. Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like Fidelity, GV and Bpifrance, among others. *

 

Period Start 2016-01-01 established
Products Industry artificial intelligence (AI) / machine learning (ML)
  Industry 2 Owkin Socrates
Person Person Clozel, Thomas (Owkin 202111 CEO + Co-Founder)
     
Region Region Paris
  Country France
  Street 12 Rue Martel
  City 75010 New York, NY
    Address record changed: 2024-01-05
     
Basic data Employees n. a.
     
    * Document for »About Section«: Owkin. (3/21/24). "Press Release: Owkin Expands Collaboration with Sanofi Leveraging AI for Drug Positioning in immunology".
     
   
Record changed: 2024-03-30

Advertisement

Picture Berlin Partner Voices Tim Huse BIH Digital Health 650x200px

More documents for Owkin (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture biomindz Mainz Biomed LSE Colorectal Cancer Screening 650x300px




» top